Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dilanubicel in Cord Blood Transplantation
NCT01690520Phase 2Completed
- Sponsor
- Nohla Therapeutics
- Start
- Dec 2012
- Primary completion
- Sep 2018
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Hematopoietic Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of dilanubicel in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), myelodysplastic syndrome (MDS), sponsored by Nohla Therapeutics. Started Dec 2012; status: completed.
02
Drugs
dilanubicel
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myelogenous leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01690520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01690520.